12,372 trials
Melanoma
Primary: Recurrence-free Survival (RFS) - All Randomized Participants — NA; NA Months
COPD Asthma
Primary: Total Number of Healthcare Visits — 111; 76; 119; 93 Participants
Unilateral Cataract Extraction · Congenital Cataract
Primary: Intraoperative Pupil Diameter — 0.14; 0.20 millimeters*minutes
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
Schizophrenia
Primary: Number of Subjects With Adverse Events — 161; 93; 61; 7 Participants
Rheumatoid Arthritis
Primary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response — 96; 84; 28 Participants — p=0.004
Heart Failure
Primary: Time to Cardiovascular Death or First Heart Failure Event — 39.1; 37.0 percentage of participants — p=0.0252
Polycythemia Vera
Primary: Number of Participants Achieving Hematocrit (Hct) Control at Week 28 — 46; 14 Participants
Surgical Skin Preparation
Primary: Bacterial Reduction — 4.83; 4.78; 2.23 log10 CFU/cm^2
ADHD
Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 143; 108; 6; 2 Participants
Acute Gouty Arthritis
Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants
Thyroid Eye Disease
Primary: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24 — 89.2; 53.8 percentage…
Primary Hyperoxaluria · Primary Hyperoxaluria Type 1 (PH1)
Primary: Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 — -71.97 percent change
Chronic Kidney Disease
Primary: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death — 504…
Migraine
Primary: Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE) — 92.0; 88.0 percentage of participants